Biosynth Carbosynth completed the acquisition of Aalto Bio Reagents.

Biosynth Carbosynth, a supplier of critical materials to the life science industry, completed the acquisition of Aalto Bio Reagents, a developer and provider of biological materials to the in-vitro diagnostic. Financial terms were not disclosed. “We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future,” Philip Noone, Aalto CEO.